Related Experiment Video
Updated: Apr 15, 2026
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
A phase I study of MEDI4736, NNT-PD-L1 antibody in patients with advanced solid tumors
11 Clinical Division of Oncology and Chairman, Department of Medicine I, 2 Comprehensive Cancer Center, Medical University Vienna, General Hospital, Vienna, Austria ; 3 Central European Cooperative Oncology Group, Vienna, Austria.
Abstract:
A review and critical consideration of immunotherapeutical concepts in non-small cell lung cancer (NSCLC) is given. Nivolumab represents a promising option in various malignancies with more results exceeding treatment of metastatic malignant melanoma eagerly awaited.
Insights
Immunotherapy shows promise for non-small cell lung cancer (NSCLC). Nivolumab is a key drug being studied for various cancers, with results for melanoma eagerly awaited.
Area of Science:
- Oncology
- Immunology
Background:
- Non-small cell lung cancer (NSCLC) remains a significant oncological challenge.
- Immunotherapy has emerged as a critical treatment modality in oncology.
Purpose of the Study:
- To critically review immunotherapeutical concepts in NSCLC.
- To evaluate the potential of immunotherapeutic agents like Nivolumab.
Main Methods:
- Literature review of current immunotherapeutic strategies.
- Critical analysis of clinical data for immunotherapies in NSCLC.
Main Results:
- Nivolumab demonstrates promise as an immunotherapeutic option.
- Further clinical data is anticipated for Nivolumab in various malignancies, including NSCLC.
Conclusions:
- Immunotherapy, particularly with agents like Nivolumab, offers a promising avenue for NSCLC treatment.
- Ongoing research and clinical trials are essential to fully elucidate the role of Nivolumab in cancer therapy.
